Compound guide · Tier C
Cerebrolysin
A registered medicine in dozens of countries, derived from pig brain, and the one product here where a purity percentage is close to meaningless.
The short answer
Cerebrolysin is the odd one out in this catalogue in a way that matters practically. It is not a synthetic peptide of known sequence but a standardised enzymatic breakdown of porcine brain tissue, a mixture of low molecular weight peptides and amino acids. It has genuine registration in around 44 countries and decades of clinical use for stroke, brain injury and dementia. Western evidence assessments have been considerably more equivocal than that footprint suggests, and it has never been approved by the FDA or centrally by the EMA. The practical consequence for a buyer is unusual: because the product is a mixture, an HPLC purity figure of 98% or 99% cannot describe it in the way it describes a single peptide, and an animal tissue origin raises identity and contamination questions that synthesis does not.
At a glance
| Class | Porcine brain derived peptide preparation, a mixture rather than a single peptide |
| Developer | Ever Pharma |
| Sold as | Cerebrolysin |
| Regulatory status | Approved in roughly 44 countries and in neither of the two that matter most for this site's readers. Cerebrolysin is a registered prescription pharmaceutical across Russia, China, Korea, Mexico and much of Eastern Europe including Romania, Poland, Ukraine, Hungary and Bulgaria, with indications typically covering ischaemic stroke, traumatic brain injury, vascular dementia and dementia of the Alzheimer type. It is not FDA approved and it is not centrally authorised by the EMA. |
| Compounding status | Cerebrolysin cannot meaningfully be compounded, because it is not a synthetic peptide. It is a standardised preparation derived from porcine brain tissue, and that manufacturing origin is the single most important thing to understand about it. |
| Anti-doping | Not specifically named on the prohibited list. |
| Our evidence tier | Tier C. Weak human data |
What it is
Cerebrolysin is produced by controlled enzymatic breakdown of purified porcine brain proteins, yielding a mixture of low molecular weight neuropeptides and free amino acids. It is administered as a solution by injection or infusion. The claimed mechanism is neurotrophic, described as mimicking the action of endogenous growth factors, which is a mechanism attributed to a mixture rather than to an identified active molecule.
Who it is for, and who actually takes it
In the countries where it is registered, the approved populations are patients with ischaemic stroke, traumatic brain injury, vascular dementia and Alzheimer type dementia, and in some markets children with perinatal brain injury. These are supervised clinical settings.
It is bought by healthy adults as a nootropic, for cognition, recovery and neuroprotection, entirely outside any registered indication and usually without any awareness of what the preparation actually is.
What the research shows
The trial literature is large, heterogeneous and independently assessed as equivocal. Selecting one trial to chart would misrepresent a body of evidence whose defining feature is inconsistency.
Dosing
| Stage | Dose |
|---|---|
| Registered indications | Ischaemic stroke, traumatic brain injury, vascular and Alzheimer type dementia, and in some markets paediatric perinatal brain injury |
| Registered in | Approximately 44 countries, including Russia, China, Korea, Mexico and much of Eastern Europe |
| Not registered by | The FDA, and not centrally authorised by the EMA |
| Route | Intramuscular injection or intravenous infusion, in clinical settings |
| Form | Solution, not a lyophilised single peptide |
We record the registered indications and route rather than a schedule, because the registrations are national with differing labelling and there is no single published label to reproduce. Note that the registered product is a solution given in clinical settings, frequently by infusion, which is not what a research vial provides. We publish no reconstitution guidance.
What happens when you come off it
In the registered indications, treatment is given as defined courses in acute and rehabilitation settings rather than continuously, so discontinuation is built into the intended use. There is no controlled evidence about what happens when healthy users taking it as a nootropic stop.
What it is being studied for
| Area | Stage of evidence |
|---|---|
| Ischaemic stroke | Registered indication in many countries, Western evidence assessments equivocal |
| Traumatic brain injury | Registered indication in many countries |
| Vascular dementia | Registered indication in many countries |
| Alzheimer type dementia | Registered indication in many countries, Western assessments equivocal |
| Cognitive enhancement in healthy adults | No approved indication and no controlled evidence |
There is a substantial trial literature and independent systematic assessment has repeatedly concluded that the evidence is weaker than the breadth of registration implies. A wide regulatory footprint and a convincing evidence base are not the same thing, and here they diverge.
Common myths
It is approved in 44 countries, so it must work.
Breadth of registration reflects regulatory history and regional practice as much as evidence strength. Independent systematic reviews have been considerably more cautious than the registration footprint suggests, and neither the FDA nor a central EMA authorisation is among those 44.
It is a peptide like the others on this site.
It is not. It is an enzymatic hydrolysate of porcine brain tissue, a mixture of many peptides and amino acids rather than one synthesised molecule of known sequence. That difference changes what testing can tell you about it.
A 98% purity certificate confirms the product.
Purity of what? The product is a mixture by design. A single purity percentage cannot characterise it the way it characterises a synthetic peptide, and a certificate presenting one should make you ask what exactly was measured.
Animal derived means natural and therefore safer.
Animal tissue origin introduces contamination and immunogenicity considerations that chemical synthesis avoids entirely. It is a reason for more scrutiny of the manufacturing chain, not less.
Verifying a purchase
Apply different thinking here. For a synthetic peptide you confirm one molecule by mass spectrometry. Cerebrolysin is a defined mixture derived from animal tissue, so the questions that matter are about the manufacturing process, batch to batch consistency of the preparation, and the controls applied to the biological starting material. A high purity percentage on a mixture is not an answer to any of those questions, and if the documentation offers only that, it has not told you what you need to know.
The general method is set out in our guide to reading a certificate of analysis, which covers the eleven checks that apply to any compound. The points above are the ones specific to Cerebrolysin.
Caveats and safety
Porcine tissue origin carries considerations that synthetic peptides do not, including immunogenicity and the integrity of the biological supply chain. The registered product is given under clinical supervision, frequently by infusion, in patients with acute neurological injury. Independent evidence assessments of benefit have been equivocal, which means the risk side of the calculation is being weighed against a benefit that is itself uncertain.
Where to get it
Where to get it
CertaPeptides Romania, EU. Volume discounts at 3+, 5+ and 10+ units.
| Vial | Price |
|---|---|
| 60 mg | €28.99 |
Stated purity. ≥98% stated batch specification. Treat that figure with care on a preparation that is a mixture by design rather than a single synthesised peptide.
Documentation. Selected lots independently tested by Janoshik Analytical (Czech Republic), HPLC plus mass spectrometry, reports searchable on the Janoshik public portal and at certapeptides.com/verify.
Cerebrolysin is sold as laboratory research material. The vendor states it is not for human consumption and that it is not approved by the FDA, the EMA or any other regulator for use in humans or animals. Read the evidence tier at the top of this page before the price.
View Cerebrolysin at CertaPeptidesAffiliate link. We earn a commission if you buy, at no extra cost to you. It does not change a word of the assessment above. Every product we have priced, in one list.
Sources
- European Medicines Agency medicine records, for absence of central authorisation
- Drugs@FDA, for absence of approval
- Cerebrolysin literature and systematic reviews, PubMed
- Registered cerebrolysin trials, ClinicalTrials.gov
Related compounds
Disclosure. PeptoPurity is an affiliate of CertaPeptides and earns a commission on qualifying purchases made through the vendor link on this page, at no additional cost to you. That relationship does not set the evidence tier, alter the verdict, or change a word of the assessment. Our Tier C and Tier D pages carry the same links as our Tier A pages, with the same conclusions we would publish if we earned nothing. Where the registered, prescribed route is the better option, we say so on the page that would otherwise pay us.
Scope. This is an evidence review, not medical advice. Where an approved label schedule is reproduced it is a record of what a regulator has published about a licensed medicine, not a recommendation and not a schedule for anyone to follow unsupervised. For unapproved compounds we report only the doses used in published studies, attributed to those studies, and we publish no protocols and no reconstitution guidance for any compound. Regulatory status differs between countries and changes over time. Material sold for laboratory research is not approved for human use. Decisions about treatment belong with a qualified prescriber.